What is the recommended treatment for Borrelia burgdorferi infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Borrelia burgdorferi Infection (Lyme Disease)

Doxycycline is the first-line treatment for Borrelia burgdorferi infection in adults and children ≥8 years of age, with amoxicillin and cefuroxime axetil as alternatives for those who cannot take doxycycline. 1

First-Line Treatment Options

Adults and Children ≥8 years:

  • Doxycycline: 100 mg twice daily for 14-21 days 1
    • Preferred due to excellent efficacy against B. burgdorferi
    • Also effective against potential co-infections like Anaplasma phagocytophilum

Children <8 years, Pregnant Women, and Doxycycline-Intolerant Patients:

  • Amoxicillin: 500 mg three times daily for adults; 50 mg/kg/day divided into 3 doses for children 1
  • Cefuroxime axetil: 500 mg twice daily for adults; 30 mg/kg/day divided into 2 doses for children 1

Treatment Based on Disease Manifestation

Early Localized Disease (Erythema Migrans):

  • Oral therapy as above for 14-21 days 1

Neurologic Manifestations:

  • Facial nerve palsy without CSF abnormalities: Oral regimen as for erythema migrans for 14 days 1
  • Meningitis or radiculopathy: IV ceftriaxone 2g daily for 14 days (range 10-28 days) 1

Lyme Carditis:

  • Symptomatic patients: IV ceftriaxone 2g daily for 14-21 days with hospitalization and continuous ECG monitoring 1
  • Asymptomatic or minimally symptomatic: Oral regimen may be sufficient 1

Lyme Arthritis:

  • Oral regimen for 28 days 1
  • For persistent arthritis after initial therapy: second course of oral antibiotics or IV ceftriaxone for 14-28 days 1

Important Clinical Considerations

Treatment Monitoring:

  • Clinical reassessment at 7-10 days to ensure symptom improvement 1
  • Monitor for adverse effects such as photosensitivity and gastrointestinal symptoms 1

Treatment Response:

  • Fever typically subsides within 24-48 hours after appropriate treatment 2
  • Lack of response within 48 hours of early treatment with doxycycline may indicate an alternative diagnosis 2

Treatment Failure:

  • Treatment failure after appropriate therapy is approximately 1% 1
  • Persistent IgM antibodies are common (up to 56% of patients at 6 months) and do not indicate treatment failure 1

Pitfalls to Avoid:

  1. Delaying treatment: Initiate empiric therapy immediately when Lyme disease is suspected based on clinical and epidemiologic findings 2
  2. Using ineffective antibiotics: First-generation cephalosporins like cephalexin are ineffective against B. burgdorferi 1
  3. Extended or combination therapy: Extended antibiotic courses beyond recommended durations or combination antibiotic therapy for routine cases are not recommended 1
  4. Treating persistent symptoms without evidence of active infection: Additional antibiotics for persistent non-specific symptoms without objective evidence of active infection are not supported by evidence 1

Special Populations

Pregnant Women:

  • Doxycycline is contraindicated
  • Amoxicillin or cefuroxime are preferred options 1

Children:

  • For children <8 years: amoxicillin or cefuroxime 1
  • For children ≥8 years: doxycycline, amoxicillin, or cefuroxime 1, 3
  • Recent evidence suggests equal effectiveness of doxycycline and ceftriaxone in pediatric Lyme neuroborreliosis regardless of age 3

By following these evidence-based treatment recommendations, clinicians can effectively manage Borrelia burgdorferi infections while minimizing complications and improving patient outcomes.

References

Guideline

Lyme Disease Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.